# EDGAR Filing Document

**Accession Number:** 0001023459
**File Stem:** 0001023459-25-000036
**Filing Date:** 2025-6
**Character Count:** 13557
**Document Hash:** b978084c41eda2138f1ca4762035cb32
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001023459-25-000036.hdr.sgml**: 20250611

**ACCESSION NUMBER**: 0001023459-25-000036

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20250611

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250611

**DATE AS OF CHANGE**: 20250611

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Simulations Plus, Inc.
- **CENTRAL INDEX KEY:** 0001023459
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 954595609
- **FISCAL YEAR END:** 0831

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-32046
- **FILM NUMBER:** 251040562

**BUSINESS ADDRESS:**
- **STREET 1:** 800 PARK OFFICES DRIVE, SUITE 401
- **CITY:** RESEARCH TRIANGLE PARK
- **STATE:** NC
- **ZIP:** 27709
- **BUSINESS PHONE:** 661-723-7723

**MAIL ADDRESS:**
- **STREET 1:** 800 PARK OFFICES DRIVE, SUITE 401
- **CITY:** RESEARCH TRIANGLE PARK
- **STATE:** NC
- **ZIP:** 27709

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SIMULATIONS PLUS INC
- **DATE OF NAME CHANGE:** 19960923

?xml version='1.0' encoding='ASCII'? slp-20250611

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**June 11, 2025**

(Date of the earliest event reported)

![SLP_TopLogo.gif](slp-20250611_g1.gif)

**Simulations Plus, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **California** | **001-32046** | **95-4595609** |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

**800 Park Offices Drive, Suite 401, Research Triangle Park, NC 27709**

(Address of principal executive offices) (Zip Code)

**661-723-7723**

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14z-12 under Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **<u>Title of each class</u>** | **<u>Trading Symbol(s)</u>** | **<u>Name of each exchange on which registered</u>** |
| Common Stock, par value $0.001 per share | SLP | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

------

**Item 7.01&nbsp;&nbsp;&nbsp;&nbsp;Regulation FD Disclosure**

On June 11, 2025 Simulations Plus, Inc. (the "Company") issued a press release announcing certain preliminary operational results for its third fiscal quarter and updating its guidance ranges for the fiscal year ending August 31, 2025. A copy of such press release is attached hereto as Exhibit 99.1.

The information in Item 7.01 of this Current Report on Form 8-K and the exhibit attached hereto is intended to be "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Except as shall be expressly set forth by specific reference in such filing, the information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits**

(d)&nbsp;&nbsp;&nbsp;&nbsp;Exhibits

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 99.1 | <u>[Press Release - June 11, 2025](pressrelease61125.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
| | **SIMULATIONS PLUS, INC.** |
| Dated: June 11, 2025 | <u>By: /s/</u> *<u>Will Frederick</u>* |
|  | Will Frederick |
|  | Executive Vice President and Chief Financial Officer |

---

## Exhibit 99.1

![image.jpg](image.jpg)

For Immediate Release:

June 11, 2025

**Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue**

*Updates fiscal 2025 revenue guidance range*

*Third quarter fiscal 2025 full results to be released on July 2, 2025, with conference call at 5 p.m. ET*

**RESEARCH TRIANGLE PARK, NC,** June 11, 2025**–** Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced preliminary revenue for its third fiscal quarter and updated its full year 2025 revenue guidance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Company expects to report third quarter fiscal 2025 revenue in the range of between $19 million and $20 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Full year fiscal 2025 revenue is expected to range between $76 million and $80 million

The third quarter fiscal 2025 revenue range set forth above is preliminary, unaudited, based on currently available information, and subject to adjustment in the final financial statements to be filed with the Company's Quarterly Report on Form 10-Q for the third quarter fiscal 2025, expected to be filed July 2, 2025.

Full year fiscal 2025 revenue guidance may also be adjusted when the Company reports third quarter fiscal 2025 results.

"Market uncertainties surrounding future funding, drug pricing and potential tariffs are creating significant headwinds for both our pharmaceutical and biotech clients, resulting in budget reductions, project cancellations, and delays that are more pronounced than what we have experienced over the past two years," said Shawn O'Connor, Chief Executive Officer of Simulations Plus. "While our software segment has remained relatively resilient, given its role as critical infrastructure in drug development programs, demand for services has proven more sensitive to market volatility and is coming in below our expectations.

"To better position the Company for long-term alignment with our clients, we recently announced a strategic reorganization—transitioning from a business unit structure to a functionally driven operating model. We also made key leadership appointments to enhance client engagement and elevate our sales and marketing capabilities.

"These actions mark the final phase of a multi-year transformation aimed at streamlining operations, unlocking synergies across teams, and concentrating our resources on the most promising growth opportunities. We believe the new organizational structure will also foster greater collaboration through centralized product and technology development, contributing to accelerated delivery of software enhancements, platform integration, and AI advancements.

"Finally, these changes are expected to improve operational efficiency and better position us for sustainable and profitable long-term growth. Looking ahead, we remain optimistic about the future of predictive analytics in biosimulation and clinical operations. These capabilities are essential to helping our clients achieve greater efficiency and success, and we are proud to be a long-standing partner and innovation leader in this space," concluded O'Connor.

------

![image.jpg](image.jpg)

**Third Quarter Fiscal 2025 Press Release, Webcast, and Conference Call Details**

The Company will report third quarter fiscal 2025 financial results after the market close on Wednesday, July 2, 2025.

Shawn O'Connor, Chief Executive Officer, and Will Frederick, Chief Financial Officer, will host a conference call and webcast on the same day at 5:00 p.m. Eastern Time to discuss the details of Simulations Plus' performance for the quarter and certain forward-looking information. The call may be accessed by registering here or by calling 1-877-451-6152 (domestic) or 1-201-389-0879 (international). The webcast can be accessed on the investor relations page of the Simulations Plus website https://www.simulations-plus.com/investorscorporate-profile/corporate-profile/ where it will also be available for replay approximately one hour following the call.

**About Simulations Plus, Inc.**

With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn \| X \| YouTube.

**Environmental, Social, and Governance (ESG)**

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update.

**Preliminary Financial Results and Financial Guidance**

The preliminary financial results set forth above for the third quarter fiscal 2025 reflect preliminary, unaudited estimates with respect to such results based solely on currently available information, which is subject to change. Such preliminary results are subject to the finalization of quarter-end financial and accounting procedures. While carrying out such procedures, Simulations Plus may identify items that would require it to make adjustments to the preliminary estimates of financial results set forth herein. As a result, our actual financial results could differ than the information set forth herein and such differences could be material. Preliminary results should not be viewed as a substitute for our full quarterly financial statements for the three months ended May 31, 2025, which are being prepared in accordance with U.S. GAAP

In addition, full year fiscal 2025 revenue guidance should not be viewed as a substitute for full financial statements prepared in accordance with GAAP.

**Forward-Looking Statements** 

Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like "believe," "will", "can", "believe", "expect," "anticipate" and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take

------

![image.jpg](image.jpg)

place, so our actual future results could differ significantly from those statements. Forward looking statements contained in this press release include, but are not limited to, the quotation of our Chief Executive Officer relating to our future performance and growth, statements relating to full fiscal year 2025 revenue guidance and other statements about future events. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our new operational structure our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission.

###

**CONTACT**:

<u>Financial Profiles</u>

Lisa Fortuna

310-622-8251

slp@finprofiles.com

<br>